Viatrice Pharmaceutical LLC (formerly known as Viatrice Pharmaceutical Co., Ltd., Pfizer UJ Co., Ltd., Pfizer Co., Ltd.)

2025.04.21 / Last updated: 2025.04.21

Viatrice Pharmaceutical LLC (Viattorice Seyak) is a corporation located at 1-3-1 Azabudai, Minato-ku, Tokyo, where Sona Kim, was founded on September 22, 2014, serves as president and representative (corporate number: 1011001064627). The final registration was updated on 2024/07/01, and the location was changed.
Trademarks such as Fargori are registered. Employees and former employees rated the review site on various job change meetings with a score of 3.7/5.0 and Kaisha's reputation with a score of 76/100.

There is no legal violation/disposition/black information posted.

Company Profile

Corporate number	1011001064627
Corporate name	Viatrice Pharmaceutical LLC
Furigana	Viatrice Seiyaku
Business overview	Manufacture, sales, import and export of medical drugs
Address/Map	〒106-0041 1-3-1 Azabudai, Minato-ku, Tokyo View on Google Maps
President/Representative	Sona Kim
URL	https://www.viatris.jp/
telephone number	Phone number: 03-5656-0400 Fax number: 03-5656-0603
Establishment	September 22, 2014
Industry	Wholesale/Retail
Corporate number designation date	2015/10/05 *Corporate numbers for corporations established before 2015/10/05 are uniformly designated as 2015/10/05.
Last registration update date	2024/07/01

Press releases and advertisements from Viatrice Pharmaceutical LLC

Ifexer SR capsules apply for additional efficacy for general anxiety disorder (GAD) -- if approved, it becomes Japan's first GAD treatment drug

To provide new treatment options for patients with general anxiety disorder (GAD) Towards the birth of Japan's first GAD treatment drug -- Ifexer SR Viatris Pharmaceutical LLC (head office: Minato-ku, Tokyo; President: Sona Kim) will be offering a new treatment option for patients with general anxiety disorder (GAD) to be a member of Japan's first GAD treatment drug ---Ifexer SR Viatris Pharmaceutical LLC (head office: Minato-ku, Tokyo; President: Sona Kim) will be offering a new treatment option for patients with general anxiety disorder (GAD) in April 2025...